Handa Pharmaceuticals, Inc. (TPEX:6620)

Market Cap	13.00B
Revenue (ttm)	830.67M
Net Income (ttm)	472.74M
Shares Out	158.31M
EPS (ttm)	3.35
PE Ratio	24.51
Forward PE	n/a
Dividend	1.50 (1.83%)
Ex-Dividend Date	Jul 2, 2025

Volume	1
Average Volume	164,405
Open	82.20
Previous Close	82.10
Day's Range	80.60 - 82.50
52-Week Range	49.90 - 95.40
Beta	0.67
RSI	47.79
Earnings Date	Aug 14, 2025

About Sage Therapeutics

Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States. The company offers ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; Tascenso ODT for the treatment of multiple sclerosis; and HND-033, HND-039, and HND-027 for oncology diseases. It also provides Quetiapine XR to treat Schizophrenia; Dexlansoprazole DR capsules to treat erosive esophagitis a...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2014
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6620

Financial Performance

In 2024, Handa Pharmaceuticals's revenue was 830.67 million, a decrease of -24.92% compared to the previous year's 1.11 billion. Earnings were 472.74 million, a decrease of -34.96%.

Financial numbers in IDR